An interventional study of silver nanoparticles reinforced double antibiotic paste and Double Antibiotic Paste in Apical Periodontitis, Post Endodontic Pain and Periapical Healing, sponsored by All India Institute of Medical Sciences. Not yet recruiting at 1 site in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by All India Institute of Medical Sciences · Not applicable, Interventional, and Treatment
Among 24 studies in Periapical Periodontitis with a site in India — 8 open to participants now, 10 under way, none of them phase 3. Periapical Periodontitis · India.
Among the 24 studies in Periapical Periodontitis with a site in India, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 20 with no phase, and was the 23rd registered.
280 studies on the registry are indexed under Periapical Periodontitis; 79 are open to participants now.
Browse Periapical Periodontitis studies →8 of the 24 studies in Periapical Periodontitis with a site in India are open now. Recruiting first, the newest first:
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 18–55 · Healthy volunteers
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 30+
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Healthy volunteers
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 18–60
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 18+ · Healthy volunteers
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 43 Periapical Periodontitis studies recruiting now, 17 (40%) set no upper age limit and 25 (58%) stop at 75 or younger; 5 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 245 interventional studies indexed under Periapical Periodontitis.
Median enrollment 74 across the 21 interventional studies, 120 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 24 has an industry lead sponsor. The 2 most frequent:
All India Institute of Medical Sciences is the lead sponsor of 27 studies on the registry; 18 are open to participants now.
All India Institute of Medical Sciences has 1 study filed under Periapical Periodontitis — fewer than ten, so there is no comparison to draw.
3 of the studies in Periapical Periodontitis with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07179835Postgraduate Institute of Dental Sciences RohtakTo Evaluate Periapical Healing Post Full Pulpotomy in Teeth With and Without Apical Periodontitis | 2027-04-15 |
| NCT07762599All India Institute of Medical SciencesSilver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Periodontitis: A Randomized Controlled Trial | 2027-06-30 |
| NCT07808424Postgraduate Institute of Dental Sciences RohtakTo Evaluate and Compare the Effect of Orthograde and Retrograde MTA Root End Filling After Periapical Surgery in Posteriors | 2027-10-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Periapical Periodontitis with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background Apical periodontitis (AP) is an inflammatory condition of the periapical tissues. The Symptomatic Apical periodontitis (SAP) represents the active phase of the disease, presenting with pain and tenderness. In SAP, levels of inflammatory mediators such as Interleukin-1β (IL-1β) and Matrix Metalloproteinase-9 (MMP-9) are elevated in gingival crevicular fluid (GCF). Assessing these biomarkers in GCF provides a novel, non-invasive method to evaluate periapical inflammation and healing. Due to the polymicrobial nature of root canal infections, the use of Intracanal medicaments (ICM) has been recommended to achieve effective disinfection. Traditionally used ICMs have their own inherent limitations. Hence, ICMs such as Triple antibiotic paste (TAP), double antibiotic paste (DAP), Silver nanoparticles (AgNPs) and their various combinations are gaining popularity. Currently, various combinations of AgNPs with other agents such as chitosan, calcium hydroxide, antibiotics and various herbal products are being tried to improve its effectiveness when used as an ICM. However, to the best of investigators knowledge, no study reinforced the DAP with AgNPs. Hence, the current double-blind, randomized, parallel clinical trial is planned to compare the effects of DAP with and without reinforcement of AgNPs on inflammatory biomarkers (IL-1β and MMP-9), postendodontic pain, and periapical healing in SAP. Moreover, this DAP+AgNPs formulation will undergo characterization such as FTIR, TEM/SEM, Zeta potential to assess its properties.
Methods A total of 50 adult participants with SAP in single-rooted teeth were randomly divided into two groups based on the type of ICM used: Group I received DAP, while Group II received DAP reinforced with AgNPs. Before starting the root canal treatment, GCF will be collected and marked as baseline. Then under rubber dam isolation all teeth underwent root canal treatment and ICM will be placed according to the specific group. Patient will be recalled after 14 days and again GCF sample will be collected after removal of the ICM. The samples will be stored at -800C for analysis. All samples will undergo enzyme-linked immunosorbent assay (ELISA) to estimate IL1β and MMP-9 levels. Pain levels will be recorded using the Numerical Rating scale (NRS) at various intervals. Data will be analyzed using STATA, SPSS or R. P value \< 0.05 will be considered statistically significant.
Discussion Most conventional ICM have limited ability to penetrate where residual microorganisms often persist. Nanoparticle-based formulations such as AgNPs have gained attention because of their extremely small size, surface charge, and potent antimicrobial activity, which enable them to penetrate dentinal tubules and disrupt bacterial biofilms that are resistant to conventional antibiotics. Incorporating AgNPs into DAP could therefore enhance their antibacterial efficacy. Furthermore, since most endodontic pathogens cannot be routinely cultivated, monitoring the changes in inflammatory biomarkers in GCF provides a reliable and non-invasive method to assess the biological response and healing. Hence, the current double-blind, randomized, parallel clinical trial is planned to compare the effects of DAP with and without reinforcement of AgNPs on inflammatory biomarkers (IL-1β and MMP-9), postendodontic pain, and periapical healing in SAP. The findings may support the use of nanoparticle-assisted ICM as a safer and more effective approach for endodontic disinfection and healing
Background and rationale Apical periodontitis (AP) is an inflammatory condition that arises from bacterial infection in the necrotic root canal system causing local inflammation of periapical tissues. The infected pulp is the primary cause of apical periodontitis, resulting in destruction of periapical tissues and bone resorption. AP can be symptomatic or asymptomatic.
Symptomatic apical periodontitis (SAP) presents with spontaneous pain, tenderness to percussion/palpation, and pain on mastication. Radiographic signs may be absent early, but inflammatory mediators like pro-inflammatory cytokines IL-1β, TNF-α, IL-6, IL-8, matrix metalloproteinases (MMP-2, MMP-8, MMP-9), and mediators such as prostaglandin E2 (PGE2), substance P, and calcitonin gene-related peptide are markedly elevated. These molecules collectively contribute to periapical tissue destruction, bone resorption, and pain perception, reflecting the active disease state and host inflammatory response. Quantifying levels of proinflammatory and anti-inflammatory cytokines involved in these immune processes holds promise as potential biomarkers to objectively assess the presence or absence of endodontic disease. Biomarkers used to assess endodontic pathology can be collected from various oral and dental sites, including the dental pulp, dentin, saliva, and gingival crevicular fluid (GCF).
The collection of GCF involves a simple, fast, and noninvasive procedure that can be completed chairside, making it a promising tool to improve diagnosis in endodontics. Inflammatory markers collected in GCF have been widely studied in recent decades IL-1β and MMP 9 significantly increased in Apical Periodontitis Moreover, the persistence of intracanal microorganisms and their by-products, even after thorough chemo-mechanical debridement, remains the primary reason for endodontic failure. Enterococcus faecalis is one of the most resistant organisms associated with persistent periapical infections due to its ability to penetrate dentinal tubules and form biofilms. Therefore ICM are essential adjuncts for disinfection between appointments in multi-visit endodontic therapy to eliminate the bacteria.
Calcium hydroxide has been the gold standard; however, it demonstrates limited activity against E. faecalis and other resistant species. Long-term use of calcium hydroxide can reduce the fracture resistance of the teeth. Antibiotics are valuable alternatives for the management of bacterial infections. During endodontic treatment antibiotics may be applied systemically or locally. Due to the ineffectiveness of systemic antibiotics in necrotic teeth, the local application of antibiotics is a more effective mode for delivery during root canal treatment.Considering the polymicrobial nature of tooth infection, single empirical antibiotics are not able to provide a bacteria-free zone in the canal. It is essential to use a combination of antibiotics against all endodontic pathogens to prevent microbial resistance. The most practical combination in order to reach a sufficient result is Triple Antibiotic Paste (TAP).
TAP containing metronidazole, ciprofloxacin and minocycline has been proposed as a root canal medicament due to its antimicrobial effects. It is more useful in reducing bacterial count than calcium hydroxide .However among the components of the mixture, minocycline can induce tooth discoloration even in low concentrations.To avoid discoloration caused by minocycline, a double antibiotic paste (DAP) made of only metronidazole, and ciprofloxacin has been proposed which showed equal effectiveness as that of TAP. DAP not only provided better antimicrobial effect but also helps in reduction in pain almost equal in efficacy to TAP Moreover residual antibacterial efficacy of DAP is longer than that of TAP. Acc to Afsaneh Rahmati et al. DAP also shows significantly better outcomes compared to calcium hydroxide as ICM in the treatment of teeth with Periapical lesions. DAP offer a more effective therapeutic approach in managing necrotic pulps and apical periodontitis, potentially improving patient outcomes and treatment success rates. American Association of Endodontists recommended the use of diluted antibiotics (TAP) in a concentration of 0.1-1 mg/ml. However bacteria remain viable in dentinal tubules of teeth with apical periodontitis and this relatively low concentrations of DAP may not be effective against established bacterial biofilm.
Recent research in nanotechnology has introduced silver nanoparticles (AgNPs) as potent antimicrobial agents. Their small particle size and high surface area enhance interaction with microbial membranes, leading to cell wall disruption, reactive oxygen species generation, and DNA interference. AgNPs also exhibit antibiofilm and potential immunomodulatory effects, which may contribute to periapical tissue healing. AgNPs as an irrigant /intracanal medicament shows a promising disinfectant. Various studies have shown that reinforcing AgNPs with different antibiotics gives synergistic effect and improve its effectiveness. Reinforcing DAP with AgNPs could therefore combine the broad antibacterial spectrum of antibiotics with the superior penetration and sustained release properties of nanoparticles. Although several studies have demonstrated the antimicrobial superiority of AgNPs-reinforced medicaments, limited clinical data exist evaluating their biological effects on host inflammatory response. Inflammatory biomarkers such as (IL-1β) and (MMP-9) in GCF serve as non-invasive indicators of periapical inflammation and healing dynamics. Evaluating changes in these biomarkers following ICM can provide valuable insights into the host response modulation and therapeutic effectiveness of the medicament.
Therefore, this study is designed to compare the effect of Double antibiotic paste -reinforced with silver nanoparticle (DAP+AgNPs) and conventional DAP on inflammatory biomarkers, post-endodontic pain, and periapical healing in SAP. The results of this randomized controlled trial may help establish an evidence-based, biologically active ICM with enhanced antimicrobial and anti-inflammatory efficacy.
Aim To compare the changes in the level of inflammatory biomarkers IL-1β,MMP-9 in gingival crevicular fluid (GCF) before \& after 14 days of intracanal medicament placement in DAP and DAP+AgNPs group, in symptomatic apical periodontitis Objectives Primary Objectives
1. To asses changes in interleukin-1β (IL-1β) and matrix metalloproteinase-9 (MMP-9) levels in gingival crevicular fluid (GCF) at baseline and after 14 days of intracanal medicament placement in DAP and DAP+AgNPs group. 2.To assess reduction in post-endodontic pain using a Numeric Rating Scale (NRS) at 24hrs, 48hrs, 72hrs, 7days and 14 days in DAP and DAP+AgNPs group. Secondary Objective 1. To evaluate radiographic periapical healing using the Periapical Index (PAI) at 3 and 6 months in DAP and DAP+AgNPs group 2. To record the incidence of flare-ups in DAP and DAP+AgNPs group.
Methods:
Trial design This study is parallel, double-blind, randomized controlled clinical trial with a 1:1 allocation ratio following a superiority framework.
Study setting The study will be conducted at the Department of Dentistry, All India Institute of Medical Sciences (AIIMS), Nagpur, Maharashtra, India. All participants will be recruited exclusively from the AIIMS Nagpur Dental Outpatient Department (OPD). Data collection, clinical interventions, and follow-up evaluations will be performed within the same institution.
Inclusion Criteria
Exclusion Criteria
Sample collection:
Oral prophylaxis will be done before starting of the treatment. GCF will be collected from the gingival crevices of each tooth diagnosed with SAP. Selected sites for GCF sampling will be cleaned with cotton rolls and a saliva ejector. The teeth surfaces will be dried gently with air spray. A Perio-paper strip will be used for collection of GCF. Sample placed in Eppendorf tubes and stored in -80°C until assayed. The sample will be collected at two times at baseline and after 14 days of treatment.
GCF samples will be obtained and tested using an IL1β, \& MMP9 ELISA kit.
Treatment procedure:
After collecting pre-operative GCF sample the treatment will be done Under rubber dam isolation, Anaesthesia will be administered. A sterile round bur will be used to excavate caries (occlusal or proximal) following verification of anaesthesia. The access cavity will prepare using a high-speed handpiece and patency will be established using a #15 K Niti file. Root canal preparation will be perform using contemporary engine-driven techniques with Niti root canal instruments. The working length (WL) will be determine using an electronic apex locator and confirm by radiographically. All canals will prepare to a size F3 (ProTaper files). Irrigation will perform with 5.25% sodium hypochlorite using a 27-G side-vented irrigation needle placed at WL-1 mm shorter. The canals will be dry with sterile absorbent paper points and a sufficient amount of the ICM (DAP +AgNPs and DAP) will be place according to the random group to completely fill the canal space up to the determined WL using a lentulo spiral instrument. The cavity will be temporarily restored with an interim restorative material. Patients will be instructed to report after 2 weeks. Patients will be asked about any signs or symptoms and clinically confirmed by checking tenderness on palpation and percussion of the tooth. In the absence of any symptoms, the temporary restoration will be removed under rubber dam isolation, and the canals will be irrigated with 5 mL of 5.25% sodium hypochlorite using a 27-G side vented irrigation needle, placed at WL-1 mm shorter. Following this, passive ultrasonic irrigation (PUI) or the XP-endo Finisher will used to remove the ICM. Canals will be dried with sterile absorbent paper points and obturation will be performed by single cone technique using gutta percha (Pro Taper Universal Conform Fit Gutta percha) and root canal sealer. Post-endodontic restoration will be done with composite resin. Using preset exposure parameters, a post-endodontic pain status at different intervals and GCF sample after 14 days of the treated tooth will be collected as per the method mentioned above and submitted for assay.
Outcomes
Clinical criteria:
Participants will be recruited consecutively as they present to the Dental OPD that meet the inclusion criteria.
Allocation Sequence generation: The allocation sequence will be generated using computer-based randomization website. The allocation sequence will be concealed using sealed opaque envelopes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In symptomatic apical periodontitis patients silver nanoparticles reinforced double antibiotic paste will placed as an intracanal medicament
Drug: silver nanoparticles reinforced double antibiotic paste
In symptomatic apical periodontitis patients double antibiotic paste will placed as an intracanal medicament
Drug: Double Antibiotic Paste
Silver nanoparticle reinforced double antibiotic paste placed as an intracanal medicament for symptomatic apical periodontitis patients distinguished by the incorporation of silver nanoparticles for enhanced antimicrobial activity compared to conventional double antibiotic paste.
Drug pages: Ciprofloxacin · Metronidazole
Standard Double Antibiotic Paste consist of ciprofloxacin and metronidazole placed as an intracanal medicament for symptomatic apical periodontitis patients .
Change in gingival crevicular fluid IL-1 beta and MMP-9 levels
IL-1 beta and MMP-9 levels will be measured in gingival crevicular fluid at baseline and after 14 days of intracanal medicament placement ,comparing DAP and DAP+ AgNPs group
Time frame: Baseline and 14 days post-treatment
Change in Post Endodontic Pain intensity
Post Endodontic Pain will be assessed using Numerical Rating Scale (NRS) at 24 hr,48hr,72hr,7 days and 14 days following intracanal medicament placement comparing DAP and DAP+AgNPs group
Time frame: Baseline and after 14 days post -treatment
Radiographic Periapical Healing
Periapical Healing will be assessed using the periapical index (PAI)at 3 months and 6 months following intracanal medicament placement ,comparing DAP and DAP+AgNPs groups.
Time frame: 3 months and 6 months post treatment
Plan to share: No — Individual participant data will not be shared due to institutional data -sharing policy constraints and the absence of an established data repository or infrastructure for external date access at this time .
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Jun 2027, 10 months later.
Of 171 non-industry interventional studies with no phase under Periapical Periodontitis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 10 months is below that.
Counting every sponsor, half of 172 studies reached it within 12 months; a quarter within 6 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
All India Institute of Medical Sciences